These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8476885)

  • 1. Vascular rejection in heart transplant recipients.
    Miller LW; Wesp A; Jennison SH; Graham MA; Martin TW; McBride LR; Pennington DG; Peigh P
    J Heart Lung Transplant; 1993; 12(2):S147-52. PubMed ID: 8476885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
    McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW
    J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular rejection in heart transplantation: clinical correlation, treatment options, and future considerations.
    Olsen SL; Wagoner LE; Hammond EH; Taylor DO; Yowell RL; Ensley RD; Bristow MR; O'Connell JB; Renlund DG
    J Heart Lung Transplant; 1993; 12(2):S135-42. PubMed ID: 8476883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of plasmapheresis for acute humoral rejection after heart transplantation.
    Wang SS; Chou NK; Ko WJ; Chi NH; Hung SC; Hsu RB; Yu HY; Chen YS; Chu SH; Tsao CI; Shun CT
    Transplant Proc; 2006 Dec; 38(10):3692-4. PubMed ID: 17175369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term development of transplant-related coronary artery disease in orthotopic cardiac allograft recipients.
    Albat B; Missov E; Serre I; Baldet P; Chaptal PA
    Minerva Cardioangiol; 1995 Oct; 43(10):435-8. PubMed ID: 8819811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
    Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
    J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Humoral rejection in heart transplantation. Report of 2 cases].
    Castro P; Arriagada G; Moreno M; Morán S; Becker P; Zalaquett R; Godoy I; Córdova S
    Rev Med Chil; 2000 Nov; 128(11):1245-9. PubMed ID: 11347512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The changing pattern of humoral rejection in cardiac transplant recipients.
    Almuti K; Haythe J; Dwyer E; Itescu S; Burke E; Green P; Marboe C; Mancini D
    Transplantation; 2007 Aug; 84(4):498-503. PubMed ID: 17713434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary concepts in noncellular rejection.
    Kobashigawa JA
    Heart Fail Clin; 2007 Jan; 3(1):11-5. PubMed ID: 17545005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide in cardiac transplant recipients with frequent rejection: a six-year retrospective review.
    Wagoner LE; Taylor DO; Olsen SL; Bristow MR; O'Connell JB; Hammond EH; Lappe DL; Renlund DG
    Clin Transplant; 1996 Oct; 10(5):437-43. PubMed ID: 8930458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of humoral immunity in acute cardiac allograft dysfunction.
    Costanzo-Nordin MR; Heroux AL; Radvany R; Koch D; Robinson JA
    J Heart Lung Transplant; 1993; 12(2):S143-6. PubMed ID: 8476884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of the first endomyocardial biopsy in heart transplantation after induction immunosuppressive therapy--experience from Canadian Heart Transplant Centre.
    Málek F; Kaan A; Straatman L; Cheung A; Gnaszewski A
    Cas Lek Cesk; 2005; 144(8):507-9; discussion 509. PubMed ID: 16173602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up.
    Stojanovic I; Vrtovec B; Radovancevic B; Radovancevic R; Yazdanbakhsh AP; Thomas CD; Frazier OH
    J Heart Lung Transplant; 2005 Sep; 24(9):1235-8. PubMed ID: 16143239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe cardiac allograft dysfunction without endomyocardial biopsy signs of cellular rejection: incidence and management.
    Veiga Barreiro A; Crespo Leiro M; Doménech García N; Paniagua MJ; Vázquez Martul E; González Cuesta M; Ramírez C; Juffé Stein A; Castro Beiras A
    Transplant Proc; 2004 Apr; 36(3):778-9. PubMed ID: 15110660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial.
    Volpin R; Angeli P; Galioto A; Fasolato S; Neri D; Barbazza F; Merenda R; Del Piccolo F; Strazzabosco M; Casagrande F; Feltracco P; Sticca A; Merkel C; Gerunda G; Gatta A
    Liver Transpl; 2002 Jun; 8(6):527-34. PubMed ID: 12037783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review.
    Kaczmarek I; Deutsch MA; Sadoni S; Brenner P; Schmauss D; Daebritz SH; Weiss M; Meiser BM; Reichart B
    J Heart Lung Transplant; 2007 May; 26(5):511-5. PubMed ID: 17449422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival.
    Gonzalez-Stawinski GV; Cook DJ; Chang AS; Banbury MK; Navia JL; Hoercher K; Lober C; Atik FA; Taylor DO; Yamani MH; Young JB; Starling RC; Smedira NG
    J Heart Lung Transplant; 2006 Jun; 25(6):613-8. PubMed ID: 16730565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.
    George JF; Kirklin JK; Shroyer TW; Naftel DC; Bourge RC; McGiffin DC; White-Williams C; Noreuil T
    J Heart Lung Transplant; 1995; 14(5):856-64. PubMed ID: 8800720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
    Aubert V; Venetz JP; Pantaleo G; Pascual M
    Hum Immunol; 2009 Aug; 70(8):580-3. PubMed ID: 19375474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.